3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
2
Breast
2
Sarcoma
1
Lymphoid
1
Head & Neck
1
Conditions
Lymphoma
8
Lymphoma, Extranodal NK-T-Cell
6
Neoplasm Metastasis
3
Sarcoma
2
Lymphoma, Large B-Cell, Diffuse
2
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Liver Neoplasms
1
Immunoblastic Lymphadenopathy
1
Head and Neck Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Drug Therapy
3
Therapeutics
2
Radiotherapy
2
Methods
2
Ipilimumab
2
Capecitabine
2
Biopsy
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tanespimycin
1
spartalizumab
1
sapanisertib
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
motexafin gadolinium
1
methoxyamine
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
entinostat
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
spartalizumab
×
Lymphoid
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts